Brief: Diagnos says cardiovascular artery disease prevention score development six to twelve months ahead of schedule
19/09/2017 14:05
Sept 19 (Reuters) - Diagnos Inc ADK.V
* Diagnos - cardiovascular artery disease prevention score
development six to twelve months ahead of schedule; commercial
launch in first half of 2018
Source text for Eikon: ID:nCCN29CGQa
Further company coverage: ADK.V
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Diagnos
See all newsBrief: Diagnos Submits Modified And Updated Health Canada Licence Application For Cara System Platform
Brief: Diagnos To Submit Future CARA Version To FDA Before End Of Q3
Brief: Diagnos Welcomes Dr. Pierre-Luc Charlebois To Its Advisory Board
Brief: Validated For Global Scale Diagnos Passes Annual MDSAP Audit, Solidifying The Pathway To Approvals With Health Canada & FDA
Brief: Diagnos Provides Update On Its Health Canada Medical Device Licence Application